Table 11.
Changes of body mass index, blood pressure and lipids profiles before and after ezetimibe treatments in high homeostasis model assessment of insulin resistance group
| Metabolic factors | Baseline | 24 weeks | P-value |
|---|---|---|---|
| BMI (kg/m2) | 28.5 ± 3.4 | 27.8 ± 3.7 | 0.002 |
| Systolic blood pressure (mmHg) | 135.8 ± 14.6 | 132.9 ± 13.2 | 0.378 |
| Diastolic blood pressure (mmHg) | 86.8 ± 9.7 | 76.8 ± 9.5 | <0.001 |
| Triglycerides (mg/dL)* | 187.9 (68–371) | 140.5 (54–777) | 0.024 |
| HDL-cholesterol (mg/dL) | 46.5 ± 9.9 | 48.5 ± 10.7 | 0.193 |
| Non-HDL-cholesterol (mg/dL) | 166.6 ± 32.3 | 137.5 ± 32.7 | <0.001 |
| LDL-cholesterol (mg/dL) | 127.1 ± 26.9 | 104.7 ± 28.5 | <0.001 |
BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
*
Data are means ± SD, geometric mean and range. These variables are shown in the original scale after analysis using log (natural)-transformed values.